Angiotensin-converting enzyme inhibitor versus angiotensin 2 receptor antagonist therapy and the influence of angiotensin-converting enzyme gene polymorphism in IgA nephritis.
- Author:
Keng-Thye WOO
1
;
Yeow-Kok LAU
;
Choong-Meng CHAN
;
Kok-Seng WONG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Angiotensin II Type 1 Receptor Blockers; therapeutic use; Angiotensin-Converting Enzyme Inhibitors; therapeutic use; Case-Control Studies; Disease Progression; Female; Genetic Predisposition to Disease; genetics; Glomerulonephritis, IGA; complications; drug therapy; genetics; Humans; Hypertension; complications; drug therapy; Kidney Failure, Chronic; etiology; Male; Peptidyl-Dipeptidase A; genetics; Polymorphism, Genetic; genetics; Retrospective Studies
- From:Annals of the Academy of Medicine, Singapore 2008;37(5):372-376
- CountrySingapore
- Language:English
-
Abstract:
INTRODUCTIONIn this study of 109 patients with IgA nephritis (IgAN), we compared the longterm effects on patients treated with angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor antagonist (ATRA) alone with respect to renal outcome in terms of ESRF from 1995 to 2006. The renal outcome is also correlated with the ACE gene ID polymorphism to study its influence on response to ACEI/ATRA therapy.
MATERIALS AND METHODSSeventy-seven patients were on treatment with ACEI/ATRA (22 on ACEI alone, 47 on ATRA alone and 8 on both). The other 32 patients were on no treatment (control group).
RESULTSCompared to controls, treated patients had lower serum creatinine (P <0.001), lower proteinuria (P <0.001) and fewer number progressing to ESRF (P <0.001). For those with the II and ID genotype there were significantly fewer patients with ESRF in the treatment group. With the DD genotype, treatment did not change the poor renal outcome with regard to ESRF. Patients on ACEI therapy had a higher incidence of ESRF compared to those on ATRA (P <0.001). For the control group, the projected number of years-to-ESRF was 10 years. For those on ACEI therapy it was 11 years, and for those on ATRA therapy it was 24 years. Among patients with the II genotype, those treated with ATRA had significantly less incidence of ESRF compared to those treated with ACEI (P <0.001).
CONCLUSIONATRA therapy was found to be effective in retarding disease progression to ESRF in IgAN compared to ACEI therapy. Genotyping showed better response to ATRA therapy only for those with the II genotype.
